The Effect of ERAS on Pancreaticoduodenectomy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

276 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-03-04

Study Completion Date

2017-05-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Enhanced Recovery After Surgery (ERAS) is not the program that aim to reduce postoperative hospital stay, but the multimodal strategies that aim to attenuate the loss of, and improve the restoration of,functional capacity after surgery on evidence-based medicine. The benefits of ERAS is proved in many surgical procedures, such as upper gastrointestinal surgery and colorectal surgery. However, pancreaticoduodenectomy (PD, Whipple's operation) is still one of most complex abdominal surgery, and there is no evidence that ERAS is beneficial on PD.

This study investigate the clinical effectiveness of ERAS on PD.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effect of ERAS on Pancreaticoduodenectomy (v2.0)

NCT06009224

Periampullary Cancer Borderline Malignancy Tumor

NOT_YET_RECRUITING NA

ERAS Program Improves Recovery of HCC Patient Undergoing Hepatectomy

NCT03104920

HCC

UNKNOWN NA

Effect of Enhanced Recovery After Surgery(ERAS) After Liver Resection for Primary Liver Cancer

NCT02644603

Carcinoma, Hepatocellular

UNKNOWN NA

Effect of an Enhanced Recovery After Surgery Program on Outcomes After Pancreatoduodenectomy

NCT06935448

Pancreatectomy Enhanced Recovery After Surgery Pancreatic Cancer Resectable

RECRUITING

ERAS® Guidelines Validation of CRS With or Without HIPEC

NCT05185791

Peritoneal Diseases

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* This study conduct totally 276 patients who underwent PD with borderline or malignant periampullary tumor. The patients divided into two groups. One group take conventional, experienced-based perioperative management, the other group take perioperative management based on ERAS protocol. Applied ERAS protocol is based on "Guidelines for Perioperative Care for Pancreaticoduodenectomy: Ehanced Recovery After Surgery Society Recommendations.
* The outcomes are analyzed for short-term surgical outcomes including operative factors, nutritional status, morbidity, mortality, length of stay, readmission, etc.
* Among all subjects who were randomized and started any study intervention (ERAS or standard perioperative management), the patients who underwent pancreaticoduodenectomy were included as the Full analysis set (FAS). All subjects who didn't undergo pancreaticoduodenectomy were excluded from this study.
* Besides, as all subjects who were randomized and received any study intervention were obliged to follow the study protocol and monitored for best compliance, per-protocol set or safety set were not defined differently

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Periampullary Tumor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Two study groups (Control (conventional) group and study (intervention) group) were randomly allocated and assigned to one of two groups in parallel for the whole duration of this study.

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

The evaluation and judgement for morbidity (primary endpoint) / mortality (secondary endpoint) was made by Morbidity and Mortality Committee in our division. Committee members were blinded about knowledge of the interventions assigned to individual participants.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Conventional perioperative management

* Preop usual biliary drainage
* Preop smoking and alcohol
* Preop parenteral nutrition
* Oral bowel preparation (mechanical bowel preparation )
* Preoperative fasting \> 12 hours
* Pre-anesthetic medication
* Anti-thrombotic prophylaxis
* Antimicrobial prophylaxis and skin preparation
* Intravenous analgesia : PCA
* Prevention of postoperative nausea and vomiting (PONV) (X)
* Incision : surgeon direction
* Avoiding hypothermia
* Nasogastric intubation (O)
* Postop glycemic control
* Positive fluid balance
* Perianastomotic drain removal over POD #5
* Somatostatin analogues
* Transurethral catheter removal
* Delayed gastric emptying(DGE) (+) , parenteral nutrition (+)
* Postop routine artificial nutrition (O), soft diet at POD #5
* Early and scheduled mobilization

Group Type NO_INTERVENTION

No interventions assigned to this group

ERAS perioperative management

* behavioral intervention (counselling, audit)
* dietary supplement
* procedure (preoperative and postoperative)
* drug

Group Type EXPERIMENTAL

ERAS perioperative management

Intervention Type OTHER

* Preop Counseling
* Preop biliary drainage (X) when Serum Total bilirubin \< 14.62mg/dl and cholangitis (-)
* Preop enteral nutrition
* Oral bowel preparation (mechanical bowel preparation ) (X)
* Preop fasting \< 6 hours
* Prevention of postoperative nausea and vomiting (PONV) (O)
* Nasogastric intubation (X)
* Near-zero fluid balance
* Somatostatin analogues (X)
* Postop routine artificial nutrition (X), soft diet at POD #2
* Audit
* Other items are same as conventional

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ERAS perioperative management

* Preop Counseling
* Preop biliary drainage (X) when Serum Total bilirubin \< 14.62mg/dl and cholangitis (-)
* Preop enteral nutrition
* Oral bowel preparation (mechanical bowel preparation ) (X)
* Preop fasting \< 6 hours
* Prevention of postoperative nausea and vomiting (PONV) (O)
* Nasogastric intubation (X)
* Near-zero fluid balance
* Somatostatin analogues (X)
* Postop routine artificial nutrition (X), soft diet at POD #2
* Audit
* Other items are same as conventional

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Fast tract

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* \>18 years old or \<75 years old
* ECOG 0-2
* resectable periampullary cancer or borderline malignancy
* no distant metastasis
* no functional disturbance in bone marrow; WBC at least 3,000/mm3 or absolute neutrophil count at least 1,500/mm3, Platelet count at least 125,000/mm3
* no functional disturtance in liver; Bilirubin less than 2.5 mg/dL AST less than 5 times upper limit of normal
* no function disturbance in kidney; Creatinine no greater than 1.5 times upper limit of normal
* informed consent

Exclusion Criteria

* distant metastasis (+) or recurred periampullary tumor
* active or uncontrolled infection
* uncontrolled psychiatric or neurologic problems
* alcohol or other drug addiction
* already enrolled patient in other study which affect this study
* the patient who is impossible to allow investigator's order
* pregnant or the possibility of pregnancy (+)
* uncontrolled cardiopulmonary disease
* moderate to severe comorbidity which affect on the quality of life and nutritional status (liver cirrhosis, end stage renal disease, heart failure, etc.)
* previous history of major gastrointestinal surgery (gastrectomy, colectomy, etc.)
* in preoperative period, expected combined resection of other gastrointestinal organ including portal vein

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No